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Abstract
Introduction: Some observational data suggest that the progestogen injectable contraceptive depot medroxyprogesterone
acetate (DMPA) may increase a woman’s risk of HIV acquisition but a randomized clinical trial did not find a statistically signifi-
cant increase in HIV risk for women using DMPA compared to two other methods. However, it could not rule out up to 30%
increased HIV risk for DMPA users. We evaluate changes to contraceptive method mix in South Africa under different
assumptions about the existence and strength of a possible undetected relationship between DMPA use and HIV risk.
Methods: A mathematical model was developed to simulate the ongoing HIV epidemic and contraceptive method mix in South
Africa to estimate how changes in method mix could impact HIV- and reproductive health-related outcomes. We made differ-
ent assumptions about the relationship between DMPA use and HIV risk, from no relationship to a 30% increase in HIV risk
for women using DMPA. Scenario analyses were used to investigate the impact of switching away from DMPA predominance
to new patterns of contraceptive use.
Results: In South Africa, the HIV-related benefits of reduced DMPA use could be as great as the harms of increased adverse
reproductive health outcomes over 20 years, if DMPA did increase the risk of HIV acquisition by a relative hazard of infection
of 1.1 or greater. A reduction in DMPA use among HIV-positive women would have no benefit in terms of HIV infections, but
would incur additional negative reproductive health outcomes. The most important driver of adverse reproductive health out-
comes is the proportion of women who switch away from DMPA to no contraceptive method.
Conclusions: If there is any real increased HIV risk for DMPA users that has not been detected by the recent randomized
trial, a reduction in DMPA use could reduce the ongoing number of new HIV infections. However, such a change would place
more women at risk of adverse reproductive health effects. It is imperative that these effects are minimized by focusing on
expanding access to safe, effective and acceptable alternative contraceptive methods for all women.
Keywords: HIV; hormonal contraception; theoretical models; pregnancy complications; women; South Africa
Additional information may be found under the Supporting Information tab for this article.
Received 20 January 2020; Accepted 20 August 2020
Copyright © 2020 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
1 | INTRODUCTION
Increasing access to modern contraceptive methods has been
vital to global development over the past 30 years [1,2]. The
use of safe and effective methods of contraception gives
women control over the number and timing of their pregnan-
cies, and so reduces maternal morbidity and mortality and
increases newborn and child survival rates [3,4]. However, con-
cerns have been raised over the use of the popular progesto-
gen-based intramuscular injectable depot medroxyprogesterone
acetate (DMPA) due to evidence from some observational stud-
ies suggesting that it increases a woman’s risk of HIV acquisi-
tion. A meta-analysis of the highest quality observational
studies reported a 40% increase in HIV acquisition rates for
women using DMPA compared to women not using hormonal
methods (hazard ratio (HR) = 1.40, 95% confidence interval
[CI] = 1.24 to 1.48) [5].
Recently, the “Evidence for Contraceptive Options and HIV
Outcomes” (ECHO) randomized open-label trial did not find a
statistically significant increase in HIV acquisition risk for
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women using intramuscular DMPA compared to those using
the copper intrauterine device (IUD) or the levonorgestrol
(LNG) implant [6]. In response to the new evidence, the World
Health Organization (WHO) changed the medical eligibility cri-
teria (MEC) classification for progestogen-based injectables
(including both DMPA and a second progestogen-based inject-
able, norethisterone enanthate [NET-EN]), from a “2,” signify-
ing that the "benefits generally outweigh theoretical or proven
risks" to a “1” (“no restriction for the use of the contraceptive
method”), noting that “new high-quality evidence supersedes
the low to low-moderate quality evidence from observational
studies that had been previously available to inform WHO’s
guidance” [7].
However, some have argued that a lack of statistical signifi-
cance for a positive interaction in the ECHO trial does not
preclude the possibility of some effect of DMPA on HIV acqui-
sition, merely that it reduces the chance of a strong associa-
tion [8-11], because the trial was not designed to detect a
hazard ratio below 1.5 (and post-trial analyses revealed that
an observed HR of 1.3 or above would have been statistically
significant, due to higher than expected subject retention and
HIV incidence) [12,13]. Furthermore, for ethical reasons, the
trial provided a comparison of HIV risk among DMPA users
versus users of other existing contraceptives, rather than no
contraceptive.
A Bayesian interpretation would synthesize the new evi-
dence with the existing evidence, weighting different types of
evidence according to the rigour of their study design. This
approach could, unfortunately, result in the possibility of a
small but real effect of DMPA use on HIV acquisition, which
would substantially affect a woman’s absolute HIV risk in
areas of high HIV incidence and high DMPA use.
If DMPA does increase HIV risk to some extent, continued
use could lead to additional HIV infections. However, a reduc-
tion in DMPA use to avert possible excess HIV infections
could lead to additional unintended pregnancies due to non-
use of contraception or switching to a less effective method,
with the potential for an increase in negative downstream
repercussions – for example morbidity and mortality related
to pregnancy. The benefits and risks of either option depend
on the interplay of HIV epidemiology, patterns of contracep-
tive use, quality of pregnancy and abortion care, and the mag-
nitude of any real effect of DMPA on HIV risk.
South Africa is among the countries with both the highest
DMPA use and HIV incidence [14,15]. Injectables are the
most commonly used contraceptive, representing 47% of the
modern contraceptive method mix. In 2016, 23% of all women
used an injectable method, of whom 16% used DMPA and 7%
used NET-EN [16]. DMPA use was highest among 25 to
34 year-olds. HIV incidence in South Africa was 0.93 (0.71 to
1.11) and 1.51 (1.31 to 1.71) per 100 person-years among
15- to 49- and 15- to 24-year-old women, respectively, in
2017, and 3.81 (3.45 to 4.21) per 100 person-years among
the women enrolled in ECHO [6,17].
The United States Agency for International Development
(USAID) and Imperial College London convened a meeting
with leading South African academics, policy makers and other
key stakeholders in January 2018 to develop a set of mathe-
matical modelling analyses in advance of the ECHO trial
results that would help inform any policy change needed in
the event that ECHO provided strong evidence for an
association between DMPA use and HIV risk. Although a pol-
icy change is unlikely in light of the trial results and subse-
quent revision to WHO guidelines, careful consideration
should be paid to the possibility that the trial did not detect a
smaller association between DMPA use and HIV risk. Here we
present the results of those analyses for a range of HRs that
are consistent with both the ECHO trial results and prior
observational evidence.
2 | METHODS
We calibrated a deterministic dynamic transmission model to
represent the ongoing HIV epidemic and changing contracep-
tive method mix over time in South Africa using data on age-
and sex-specific HIV prevalence, total HIV incidence, incidence
among high-risk women, and age-specific contraceptive
method mix [18,19]. The model has been described in detail
elsewhere and full details are provided in the Supporting
Information [20,21]. Key features of the model include repre-
sentation of the population age structure, sexual behaviour
(sex acts, condom use, partner change rates), HIV transmission
and natural history, rollout of the antiretroviral therapy (ART)
cascade, prevention interventions (male circumcision,
expanded condom use), contraceptive method mix and repro-
ductive health outcomes.
We assigned women to a type of contraception based on
current method mix by age, and assumed that this pattern of
use has held constant since the beginning of the HIV epidemic
(Table 1). Many methods, including injectables, oral pills and
female sterilization, have been used at broadly similar levels
since the first Demographic and Health Survey in 1998, for
example injectables (both DMPA and NET-EN) were used by
27% of all women in 1998 and 23% in 2016 [16,22]. We
parameterized the effectiveness of each method assuming the
quoted “typical use” contraceptive efficacies and one-year con-
tinuation rates, recognizing the limitation that in reality “typi-
cal use” could be country specific [18,23].
Model outputs include demographic, HIV-related and repro-
ductive health outcomes encompassing morbidities and mortality
stemming from both HIV infection and unintended pregnancy.
All modelled health outcomes are jointly summarized as disabil-
ity-adjusted life-years (DALYs). For HIV-related outcomes, these
include the different stages of HIV infection and ART use, and
for reproductive health outcomes, these include morbidities
associated with unsafe abortion and complications of labour
(haemorrhage, puerperal sepsis, eclampsia, obstructed labour),
and mortality resulting from unsafe abortion and maternal
deaths. All model simulations were run for 20 years and the
results summed for that period without discounting.
Two sources of uncertainty are included in the model out-
puts. First, several parameters defining the HIV epidemic were
fitted (per sex act probability of HIV transmission, sexual mix-
ing rates between different behavioural risk groups, the size
of these risk groups and the start time of the epidemic) by
running the model 20,000 times and using a filtration method
to select the 100 most acceptable epidemic fits, and the anal-
ysis was repeated sampling from each of these parameter
sets. Second, we sample the maternal mortality ratio (MMR)
in South Africa from a log-normal distribution constructed
using a point estimate and associated 95% CI [24].
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The association between DMPA use and HIV acquisition
risk in the model was varied between an HR of 1.0 (repre-
senting no association, consistent with the ECHO trial results)
to 1.3 (representing a 30% increase in HIV risk for women
using DMPA, consistent with both the ECHO trial results and
a meta-analysis of observational data [5,6]) at increments of
0.1, and all analyses were repeated under each assumption.
We do not consider the possibility that HR < 1 because this
would not result in any undetected ongoing excess HIV risk.
In the absence of data, we assume that the IUD and
levonorgestrel implant have no effect on risk of acquiring HIV.
Similarly, we assume that NET-EN does not affect HIV acquisi-
tion risk.
The analysis compares the HIV- and reproductive health-re-
lated outcomes in a 20-year period that could result from
changes in the contraceptive method mix from 2019. Eighteen
different scenarios, described in Table 2, were defined by
stakeholders that vary in respect of:
• the magnitude of migration away from DMPA (a “soft”
change is defined as a decrease in new DMPA users, but all
current DMPA users continuing).
• whether migration is limited to HIV-negative women or also
includes HIV-positive women (a “medium” change is defined
as when all HIV-negative women stop using DMPA, but
HIV-positive women can continue to use it; a “hard” change
is defined as when all women, HIV positive and negative,
stop using DMPA).
• the choice of replacement contraceptive – this can be an
alternative method of comparable effectiveness (and no
associated HIV risk), implant, no method, or some combina-
tion of these.
These scenarios are not intended to predict what will hap-
pen, but rather to illustrate key relationships and their poten-
tial outcomes over a wide range of assumptions. For example
it is unlikely that DMPA availability would ever be restricted
for HIV-positive women, who have limited alternative contra-
ceptive options [25].
Finally, we used an analysis of the 2016 South African HIV
Investment Case to infer the cost at which each scenario
would be cost-effective [26]. That analysis implied that HIV
interventions that lead to saving life-years at a cost of $547
to 872 per life-year saved (LYS) would be at the margin of
cost-effectiveness based on the set of interventions being
















DMPA 14.5% 94% Varied from
1 to 1.3
NET-EN 10.4% 94%a 1




Implant 0% 99.5% 1
Other methods 6.7% 83.9%b 1
a
Assumed to be the same as DMPA;
b
average of the efficacies of male
sterilization, withdrawal, fertility awareness and male condoms.
Table 2. Analysis plan
A) Magnitude of migration away from DMPA use:
Potential new starters (HIV
negative)
Potential new starters (HIV
positive)
Already using DMPA (HIV
negative)
Already using DMPA (HIV
positive)
1. “Soft change” 50% reduction in DMPA
uptake
No change in DMPA uptake Continue using DMPA
2. “Medium
change”
Do not start DMPA No change in DMPA uptake Stop using DMPA Continue using DMPA
3. “Hard
change”
Do not start DMPA Stop using DMPA
B) Contraceptive replacement for those stopping using DMPA:
1. 100% switch to an alternative method of comparable efficacy and no associated HIV risk
2. 100% switch to implant
3. 90% redistribute among other methods proportionately; 10% move to no method
4. 80% redistribute among other methods proportionately; 20% move to no method
5. 90% redistribute among other methods disproportionately in favour of NET-EN (OR = 2); 10% move to no method
6. 90% redistribute among other methods disproportionately in disfavour of NET-EN (OR = 0.5); 10% move to no method
Eighteen different scenarios are constructed by combining each of the three magnitudes of migration options (Panel A) with the six contraceptive
replacement options (Panel B). DMPA is replaced over three years from 2019 onwards. Baseline: no change in DMPA use.
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funded under the current budget. We therefore multiplied the
net health impact (in LYS) of each scenario by the cost range
above to give the total affordable cost of an intervention to
implement each switching scenario.
3 | RESULTS
Figures 1-3 show the changes in the numbers of HIV infec-
tions among women, unsafe abortions and maternal deaths
over a 20-year period, following each of the changes in the
contraceptive method mix (Table 2), under a range of different
assumptions for a possible association between HIV risk and
DMPA use.
3.1 | HIV infections
If there is no association between DMPA use and HIV risk,
the proportion of women ceasing to use DMPA has no impact
on the expected number of HIV infections (Figure 1A). How-
ever, when the HR is assumed to be greater than one,
reduced DMPA use leads to a reduction in HIV infections (Fig-
ure 1B-D). The magnitude of the reduction depends on: (i) the
strength of the risk association assumed – the greater the
HR, the greater the reduction in HIV infections when women
cease to use DMPA; and, (ii) the number of HIV-negative
women who discontinue DMPA use or do not initiate DMPA
use (the “soft” versus the “medium” and “hard” reductions).
For example for a HR of 1.1, 14,600 to 53,200 fewer HIV
infections would occur over 20 years among women (0.7% to
2.2% of projected total infections among women in this per-
iod), depending on the number of women switching away from
DMPA. The assumption regarding the replacement contracep-
tive(s) does not affect the HIV infections averted, and there is
no additional impact from reducing DMPA use among HIV-
positive women (medium vs. hard change scenario). In all
cases, the number of HIV infections averted increases over
time (Figures S13-S14).
3.2 | Unsafe abortions
In contrast to HIV infections, the strength of an association
between DMPA use and HIV risk has no impact on the num-
ber of unsafe abortions following a change in DMPA use.
Instead, this depends on the mix of replacement contraceptive
(s) and particularly the proportion of women (irrespective of
HIV status) who stop using any method (Figure 2). For exam-
ple if all DMPA users were to switch to an alternative method
(a) (b)
(c) (d)
Figure 1. Change in HIV infections among women over 20 years under different assumed HRs for DMPA-HIV risk association and different
switching assumptions. Uncertainty intervals represent 90% of variability in model outputs.
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with comparable effectiveness and no associated HIV risk
(contraceptive replacement option 1), there would be no
change in unsafe abortions because both methods have the
same effectiveness. If all ex-DMPA users switch to the implant
(replacement 2), 10,700 to 30,700 (2.0% to 5.5%) fewer
unsafe abortions would occur over 20 years because the
implant is a more effective contraceptive. But if some propor-
tion of DMPA users switch to no method, we anticipate an
increase in unsafe abortions over 20 years regardless of the
mix of other methods in use – 49,300 to 56,400 (9.1% to
10.2%) extra with 10% DMPA users moving to no method (re-
placement 3, 5 and 6) and 86,700 to 106,000 (15.9% to
19.2%) extra with 20% moving to no method (replacement 4).
The change in unsafe abortions is greater with more women
moving away from DMPA and also increases over time (Fig-
ures S15-S16).
3.3 | Maternal deaths
If DMPA use was reduced, the impact on maternal deaths
would depend on both the true association between DMPA
use and HIV acquisition risk and the contraceptive
replacement option(s). If there is no effect (HR = 1), the pat-
tern of change in maternal deaths is similar to that for unsafe
abortions, with the exception that a medium change is the
least harmful when switching to a mix of existing methods and
no method (Figure 3A). The differences between medium and
soft/hard change become more pronounced as the magnitude
of the assumed HIV risk for DMPA users increases (Fig-
ure 3B-D). This is due to the assumption that HIV-positive
women are at greater risk of maternal death; under the hard
change switching scenario, some of the women stopping
DMPA use are HIV positive which puts them at increased risk
of maternal death should they switch to no method and sub-
sequently become pregnant. In the soft and medium change
scenarios, only HIV-negative women stop DMPA use, so this
additional risk is avoided. If all women had the same MMR,
the pattern of change in maternal deaths would replicate that
of unsafe abortions.
3.4 | DALYs averted
Figure 4 (and Table S7) summarize all the health outcomes in
terms of DALYs averted in the whole population over
(a) (b)
(c) (d)
Figure 2. Change in unsafe abortions over 20 years under different assumed HRs for DMPA-HIV risk association and different switching
assumptions. Uncertainty intervals represent 90% of variability in model outputs.
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20 years under each contraceptive method mix change and
DMPA risk assumption.
The change in DALYs strongly depends on the assumed HR.
With no increased risk of HIV infection for DMPA users
(HR = 1), there is no change in DALYs when all women switch
to an alternative method of comparable effectiveness and no
associated HIV risk (Figure 4A, replacement option 1) and a
small positive health outcome (DALYs averted) when all
women switch to the implant (Figure 4A, replacement 2).
However, if 10% or 20% of DMPA users switch to no method
then there is a net negative health outcome (more DALYs)
over 20 years (Figure 4A, replacement 3 to 6).
In contrast, with an HR of 1.1 or higher, the benefits of a
switch, in terms of reduced HIV risk, outweigh the increased
adverse reproductive health outcomes, to give an overall
increase in positive health outcomes (DALYs averted) over
20 years. This holds for all the switching scenarios – whether
there is a complete replacement of contraceptive method for
former DMPA users but even if 20% of former DMPA users
move to no method. The net health gain is greatest when
more women switch to an effective method. In all cases, the
medium and hard change options (which see greater reduc-
tions in DMPA use) lead to more than twice the DALYs
averted by a soft change in DMPA provision.
3.5 | Value of a switching intervention
For the magnitude of health impact that could arise from a
reduction in DMPA use, an intervention costing up to the
order of $10M may be considered cost-effective for the South
African government as part of its HIV strategy (Table 3). For
example under the medium change scenario, if there is a real
but modest effect of DMPA on HIV risk such that HR = 1.2,
then an intervention costing less than $54.7 million USD may
be considered cost-effective. But under HR = 1.1, an interven-
tion to implement the medium change scenario would have to
cost less than $2.9 million USD to be considered cost-effec-
tive.
4 | DISCUSSION
Following the ECHO trial, we can be confident that DMPA
use does not confer a large additional HIV risk compared to
the copper IUD or LNG implant. However, a Bayesian inter-
pretation of all available evidence, including observational
studies, may not rule out a smaller increase in HIV acquisition
risk for women who use DMPA. It is therefore important for
countries to consider the possible implications and the
(a) (b)
(c) (d)
Figure 3. Change in maternal deaths over 20 years under different assumed HRs for DMPA-HIV risk association and different switching
assumptions. Uncertainty intervals represent 90% of variability in model outputs.
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communication of this potential risk to women who are con-
sidering their contraceptive choices. This is especially true for
countries such as South Africa where a high HIV incidence
rate coincides with the high use of DMPA, and thus the
impact of any true interaction would be largest. Conversely,
countries with lower HIV incidence or DMPA prevalence
would be affected less in absolute terms.
We find that if there was some undetected association
between DMPA use and HIV acquisition risk – even with an
HR as low as 1.1 – a situation where current DMPA users
switch to another highly effective form of contraceptive could
have a net health benefit over 20 years relative to the status
quo. The South African government is arguably willing to pay
up to the order of $10 million USD to secure this health gain,
depending on the true size of any increased risk, based on
other interventions that are currently funded as part of its
HIV strategy.
The number of women that migrate away from DMPA and
onto no method or a less effective method has the largest
impact on adverse reproductive health outcomes. If all women
moving away from DMPA can be efficiently transitioned onto
a replacement method with similar or greater effectiveness,
there are few if any harmful reproductive health conse-
quences of reduced DMPA use. In contrast, if 20% of women
on DMPA stop using contraception, there could be up to
106,000 extra unsafe abortions over 20 years with all other
things being equal. Larger numbers of DMPA users switching




Figure 4. DALYs averted over 20 years under different assumed HRs for DMPA-HIV risk association and different switching assumptions.
Includes net HIV-related and reproductive health DALYs. Uncertainty intervals represent 90% of variability in model outputs.
Table 3. Costs for a change in contraceptive usage consistent
with being a marginally cost-effective HIV intervention (USD,
millions)
HR Soft change Medium change Hard change
1.0a n/a to 1.2 n/a to 2.9 n/a to 38.1
1.1 0.95 to 1.1 1.1 to 2.9 9.3 to 30.2
1.2 7.2 to 20.4 26.9 to 54.7 25.3 to 55.6
1.3 13.2 to 29.5 42.2 to 79.2 40.6 to 80.1
Total cost estimated by multiplying the range of projected life-years
saved (LYS), including 90% model variability interval, over 20 years
under each assumed HR and switching scenario by the affordability
range $547-872/LYS.
a
If HR = 1.0, the overall outcome is harmful (loss of life-years) when
switching to a mix of existing methods and no method, therefore no
cost is calculated; the outcome is neutral when all women switch to
an alternative with comparable efficacy and no HIV risk; the outcome
is beneficial when all women switch to the implant.
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We also find that a reduction in DMPA use among all
women compared to only HIV-negative women (“hard” vs.
“medium” change) has no extra benefit in terms of the poten-
tial reduction in HIV infections, but does incur additional
negative reproductive health outcomes, as maternal out-
comes are worse for HIV-positive women. This suggests that
a tailored approach – focused on providing alternative con-
traceptive options to HIV-negative women – may give the
most optimal combined outcomes across different population
groups.
A synthesis of evidence would require judgement on how to
weight high-quality evidence from a randomized trial against
lower quality observational data. Furthermore, the different
study types use different populations and different compara-
tors. We therefore do not perform a formal synthesis here.
We do note, however, that the high-quality randomized data
would likely dominate a combined effect measure, resulting in
a central estimate closer to 1 than 1.3.
Balancing and comparing different forms of health outcomes,
and especially for outcomes that have consequences beyond
health, is not easy and relies to some extent on subjective
assumptions. We have done this using DALYs. However, any
decisions must weigh all considerations and in the light of
locally accepted values and principles. One particular issue is
the time-frame for the analysis; although population behaviour
and the available interventions may change substantially over
20 years, the long time-frame is necessary for the HIV-related
outcomes to accrue (including long-term ART use, AIDS deaths
and indirect infections, which also affect men). Our long-term,
population-wide view tries to take all these into account,
whereas earlier work examining effects on women in the
short-term may reveal a more partial picture [27-31].
There are inherently a number of important assumptions
that influence the results of this model. First, we have not
incorporated the full range benefits of DMPA in particular, and
contraception in general, for women to control the number
and timing of the pregnancies and in a manner that is seem-
ingly preferred by women in South Africa. We have also not
considered the economic burden of unintended pregnancies,
the adverse outcomes for children of reduced birth spacing
and the increased risk of mother-to-child transmission of HIV.
The model assumes no behavioural differences between
women choosing DMPA and women choosing other or no con-
traceptives. Such differences, if unadjusted for, may explain
the discrepant results from the randomized trial and the
observational studies, rather than simply lack of statistical
power in the trial.
The model does not explicitly account for any increased
HIV incidence during pregnancy or post-partum. Although the
physiological risk of HIV acquisition has been shown to be ele-
vated for women during these periods [32], it remains unclear
whether this translates into an increase in HIV incidence
[33,34]. If there was such an increase, the overall harms of
women switching from DMPA to no method (or a less effec-
tive method) would be larger. Whether or not this effect
would balance out any potential benefit of reduced HIV risk
from DMPA use would depend on the true underlying HR and
the pregnancy risk for women using no method or an alterna-
tive method.
We have assumed an interaction between HIV status (HIV-
positive women not on ART) and risk of maternal mortality
that is supported by some but not all of the evidence [35].
We also had to rely on incomplete data to inform many
parameters, especially those that affect the reproductive
health outcomes. We have used national estimates where pos-
sible and regional estimates otherwise. We also used data on
current patterns of contraceptive use to inform the model.
However, method mix has been broadly stable for the past
20 years, and small variations will only have a modest effect
on future projections of reproductive and HIV outcomes.
Finally, we have had to form assumptions about the nature
of HIV programmes in the future. If we have over-estimated
future HIV incidence and under-estimated the future success
of ART programmes, the benefits in HIV outcomes from a
reduced use of DMPA will have been over-estimated. ART
programs are set to grow and new initiatives such as the roll-
out of PrEP (which was not included in this model) could well
see such positive changes unfold. In such cases, the benefits
of a switch away from DMPA in reducing HIV outcomes are
reduced and may be exceeded by the concomitant increase in
adverse reproductive health outcomes.
5 | CONCLUSIONS
Many countries should consider carefully the implications of
the ECHO trial results. Both no relationship and a 30%
increase in HIV risk for women using DMPA could be consis-
tent with the totality of data, although the high-quality ran-
domized evidence points towards no association.
Nevertheless, the possibility that HR > 1 cannot be excluded
and, if true, would result in women using DMPA being subject
to an excess HIV risk. Our analysis highlights and attempts to
quantify the potential repercussions of the uncertainty around
this complex issue. Accurate communication of risk and uncer-
tainty is extremely difficult, especially in circumstances when
the strength of evidence is open to different interpretations.
Nevertheless, this uncertainty should be acknowledged and
communicated to women so that they may make their own
contraceptive choices. Ultimately, the only way to minimize
even the potential for overall harm is to continue to focus on
broadening the contraceptive method mix to provide safe,
effective and acceptable alternatives to DMPA.
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SUPPORTING INFORMATION
Additional information may be found under the Supporting
Information tab for this article.
Figure S1. Natural history of HIV infection and ART initiation
as represented in the model.
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Movement between compartments is indicated by arrows.
Figure S2. The proportion of adult men that are circumcised
with respect to time.
The level of circumcision in the model was calibrated to data
reported in a nationally representative survey.
Figure S3. The number of adults receiving antiretroviral ther-
apy in South Africa. Model data is compared to estimates of
the number of adults on ART in South Africa. Grey lines rep-
resent runs of the model using different parameter sets.
Figure S4. Maternal mortality. The model was calibrated to
estimates of MMR from the Institute of Health Metrics as
well as estimates from the South African Rapid Mortality
Surveillance. Grey lines represent model runs using different
parameter sets.
Figure S5. Population pyramids for South Africa for 1985,
1990, 1995, 2000, 2005 and 2010. Model population struc-
ture is compared to annual age-structured population size
model estimates produced by the Actuarial Society of South
Africa.
Figure S6. Population size with respect to time. The total pop-
ulation of the model was calibrated to previous model esti-
mates.
Figure S7. Model calibration to HIV prevalence data
The model was calibrated adult HIV prevalence data from a
nationally representative survey and previous estimates of
HIV prevalence. The grey lines represent different model
parameter sets.
Figure S8. Model calibration to HIV incidence data. The model
was calibrated adult HIV incidence data from a nationally rep-
resentative survey as well as previous incidence estimates
from a mathematical model. The grey lines represent different
model parameter sets.
Figure S9. Model calibration to male HIV prevalence data. The
model was calibrated adult male HIV prevalence data from a
nationally representative survey. The grey lines represent dif-
ferent model parameter sets.
Figure S10. Model calibration to female HIV prevalence data.
The model was calibrated adult female HIV prevalence data
from a nationally representative survey. The grey lines repre-
sent different model parameter sets.
Figure S11. HIV prevalence by age group (men). HIV prevalence
in the model was calibrated to sex and age-specific prevalence
data (a single-year example calibration is shown here for clarity).
Figure S12. HIV prevalence by age group (women). HIV
prevalence in the model was calibrated to sex and age-specific
prevalence data (a single-year example calibration is shown
here for clarity).
Figure S13. Change in HIV infections among women over five
years under different assumed HRs for DMPA-HIV risk associ-
ation and different switching assumptions. Uncertainty inter-
vals represent 90% of variability in model outputs.
Figure S14. Change in HIV infections among women over ten
years under different assumed HRs for DMPA-HIV risk associ-
ation and different switching assumptions. Uncertainty inter-
vals represent 90% of variability in model outputs.
Figure S15. Change in unsafe abortions over five years under
different assumed HRs for DMPA-HIV risk association and dif-
ferent switching assumptions. Uncertainty intervals represent
90% of variability in model outputs.
Figure S16. Change in unsafe abortions over ten years under
different assumed HRs for DMPA-HIV risk association and dif-
ferent switching assumptions. Uncertainty intervals represent
90% of variability in model outputs.
Figure S17. DALYs averted over five years under different
assumed HRs for DMPA-HIV risk association and different
switching assumptions.Uncertainty intervals represent 90% of
variability in model outputs.
Figure S18. DALYs averted over ten years under different
assumed HRs for DMPA-HIV risk association and different
switching assumptions. Uncertainty intervals represent 90% of
variability in model outputs.
Table S1. Natural history of infection parameters
Table S2. Behavioural parameters and values
Table S3. Factors affecting transmission probability per sex
act with respect to baseline transmission probability (b0)
Table S4. Contraceptive efficacy and continuation rates for
methods used in the model
Table S5. Parameters for reproductive health outcomes
Table S6. Calibrated parameters
Table S7. Total DALYs averted over 20 years (thousands)
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